GlassScriptPhysician profile
Joseph M Mawad
NPI 1003140948
$8,060.29
in general payments reported to CMS, 2019-2025
34 companies · $682 in 2025
The $682 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $190 · 2021: $846 · 2022: $1,183 · 2023: $3,934 · 2024: $512 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,128.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,669.65 | 2022-2023 | Davinci Xi |
| Baxter Healthcare | $769.17 | 2021-2025 | Tisseel, Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $626.90 | 2019-2024 | |
| Abbvie INC. | $409.58 | 2019-2025 | |
| Aspira Women'S Health INC | $387.57 | 2020-2024 | Ova1 |
| Coopersurgical, INC. | $354.18 | 2019-2023 | Paragard T 380a |
| Hologic Sales and Service, LLC | $265.54 | 2019-2025 | Novasure, Aptima, Thinprep 2000 Processor |
| Roche Diagnostics Corporation | $197.37 | 2019 | |
| Organon LLC | $161.74 | 2021-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $160.34 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $115.53 | 2019-2021 | |
| Biotissue Holdings INC. | $106.11 | 2023 | |
| Astellas Pharma US INC | $102.65 | 2023-2024 | Veozah |
| Pfizer INC. | $101.70 | 2024-2025 | |
| Medicem INC. | $73.65 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $53.80 | 2025 | Dexcom G6 Transmitter |
| Conmed Corporation | $53.56 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $52.40 | 2024-2025 | |
| Novo Nordisk INC | $50.23 | 2025 | Wegovy |
| Davol INC. | $48.68 | 2020-2022 | |
| Smith+Nephew, INC. | $43.48 | 2022-2025 | Stravix Pl |
| Myovant Sciences INC. | $39.70 | 2021-2022 | |
| Lilly USA, LLC | $38.35 | 2025 | Zepbound |
| Coloplast Corp | $20.20 | 2025 | |
| Sage Therapeutics, LLC | $19.88 | 2024 | |
| Meditrina | $18.91 | 2023 | |
| Shield Therapeutics INC | $18.86 | 2025 | |
| Exeltis, USA INC. | $17.13 | 2025 | Slynd |
| Minerva Surgical, INC | $16.87 | 2019 | |
| Evofem Biosciences, INC. | $16.59 | 2022 | |
| Lupin INC. | $14.93 | 2019 | |
| Dysis Medical, INC. | $12.31 | 2020 | |
| Therapeuticsmd, INC. | $11.55 | 2021 | |
| Allergan, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mawad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.